ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (ANIP) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
anip · stock forecast · 10 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Buy
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$124
Consensus
$124
+52.9% upside
Low
$124
Median: $124 · Last Close: $81.08
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $79.99 | ↓ 1.35% |
1-day model range: $79.69–$80.29. Peak: $80.29 (-1.35%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $92 | +13.7% |
| 2028 | $99 | +22.4% |
| 2029 | $103 | +27.4% |
| 2030 | $106 | +30.4% |
| 2031 | — | +32.0% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ANIP · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-01-16 | Guggenheim | Maintains | Buy→Buy |
| 2025-11-10 | Guggenheim | Maintains | Buy→Buy |
| 2025-10-09 | Truist Securities | Maintains | Hold→Hold |
| 2025-09-24 | JP Morgan | Maintains | Overweight→Overweight |
| 2025-09-17 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-09-08 | Guggenheim | Maintains | Buy→Buy |
| 2025-08-11 | Truist Securities | Maintains | Hold→Hold |
| 2025-08-08 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-05-12 | Guggenheim | Maintains | Buy→Buy |
| 2025-04-21 | Truist Securities | Maintains | Hold→Hold |
Wall Street analysts have recently issued updated ratings on ANI Pharmaceuticals, Inc. (ANIP) stock. Of the recent 74 rating actions, 1 were upgrades and 7 were downgrades. 10 analysts currently cover ANIP.
Analyst Recommendation Trends
ANIP analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1.1B
↓ 14.4% YoY
Revenue Next Year
$1.2B
↑ 11.2% YoY
EPS This Year
$9.37
EPS Next Year
$10.74
↑ 14.6% YoY
EPS ForecastReported vs Estimated
Analysts forecast ANIP EPS of $9.37 for the current fiscal year, based on estimates from 4 analysts. The ANIP revenue forecast is $1.1B for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ANIP stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ANIP price target is $124.00 (+52.9% upside), with an analyst consensus of Buy.
The ANIP short-term stock prediction for tomorrow is $79.99 (-1.35%). The ANIP stock price prediction for 2027 estimates an average of $92. The ANIP stock prediction for 2030 projects a range of $101–$110.
ANI Pharmaceuticals, Inc. trades on NASDAQ under the ticker ANIP. The ANIP stock outlook for 2027 is broadly positive, supported by a Buy consensus among 70% of covering analysts.
Frequently asked questions
ANIP forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month ANIP price target is $124.00, with a high forecast of $124.00 and a low of $124.00. The median price target is shown in the chart above when available. This implies +52.9% potential upside from the current price of $81.08.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.